AnaptysBio Says FDA Approves Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer

• AnaptysBio announced FDA approval of GSK's Jemperli, the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer.
• The AZUR-1 trial showed sustained complete responses, with a significant proportion of participants remaining cancer-free a year or more following treatment.
• No disease recurrences were reported among responders during median follow-up exceeding two years.
• Jemperli monotherapy could help eligible patients avoid chemotherapy, radiation and surgery; its safety profile was generally consistent with previous findings.
• GSK will present full interim results at the ESMO Congress in Madrid on October 25, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191418PRIMZONEFULLFEED9848660) on October 19, 2026, and is solely responsible for the information contained therein.